This site is intended for US residents only.

Results With VYLOY

How was VYLOY studied?

VYLOY (zolbetuximab-clzb) was studied in combination with chemotherapy in 2 clinical trials of patients with advanced* stomach or GEJ cancer whose tumors were HER2-negative and claudin 18.2 positive.

  • Trial 1 enrolled 565 patients. It compared 283 patients who received VYLOY with mFOLFOX6 to 282 patients who received mFOLFOX6 alone.
  • Trial 2 enrolled 507 patients. It compared 254 patients who received VYLOY with CAPOX to 253 patients who received CAPOX alone.

*Cancer that cannot be removed with surgery or has spread to other parts of the body.

Results from Trial 1: VYLOY + mFOLFOX6

DURING THE TRIAL

VYLOY + chemotherapy helped more people live without their cancer getting worse versus chemotherapy alone. 

Median progression-free survival time was 10.6 months with VYLOY + chemotherapy vs 8.7 months for chemotherapy alone

Bar chart showing a median progression free survival time of 10.6 months with VYLOY + chemotherapy and 8.7 months with chemotherapy alone
Bar chart showing a median progression free survival time of 10.6 months with VYLOY + chemotherapy and 8.7 months with chemotherapy alone

DURING THE TRIAL

VYLOY + chemotherapy helped more people live longer versus chemotherapy alone.

Median overall survival time was 18.2 months with VYLOY + chemotherapy vs 15.5 months for chemotherapy alone

AFTER THE STUDY ENDED

Some patients being treated in Trial 1 were assessed at 1 and 2 years. These results were not used to determine how well VYLOY performed and they only reflect the experience of these patients. Your experience may be different.

Progression-free survival:

At 1 year

  • 49% of patients on VYLOY + chemotherapy were progression-free
  • 35% of patients on chemotherapy alone were progression-free

At 2 years

  • 24% of patients on VYLOY + chemotherapy were progression-free
  • 15% of patients on chemotherapy alone were progression-free

Overall survival:

At 1 year

  • 68% of patients on VYLOY + chemotherapy were still alive
  • 60% of patients on chemotherapy alone were still alive

At 2 years

  • 39% of patients on VYLOY + chemotherapy were still alive
  • 28% of patients on chemotherapy alone were still alive

Results from Trial 2: VYLOY + CAPOX

DURING THE TRIAL

VYLOY + chemotherapy helped more people live without their cancer getting worse versus chemotherapy alone.

Median progression-free survival time was 8.2 months with VYLOY + chemotherapy vs 6.8 months for chemotherapy alone

Bar chart showing a median progression free survival time of 8.2 months with VYLOY + chemotherapy and 6.8 months with chemotherapy alone
Bar chart showing a median progression free survival time of 8.2 months with VYLOY + chemotherapy and 6.8 months with chemotherapy alone

DURING THE TRIAL

VYLOY + chemotherapy helped more people live longer versus chemotherapy alone. 

Median overall survival time was 14.4 months with VYLOY + chemotherapy vs 12.2 months for chemotherapy alone 

AFTER THE STUDY ENDED

Some patients being treated in Trial 2 were assessed at 1 and 2 years. These results were not used to determine how well VYLOY performed and they only reflect the experience of these patients. Your experience may be different.

Progression-free survival:

At 1 year

  • 35% of patients on VYLOY + chemotherapy were progression-free
  • 19% of patients on chemotherapy alone were progression-free

At 2 years

  • 14% of patients on VYLOY + chemotherapy were progression-free
  • 7% of patients on chemotherapy alone were progression-free

Overall survival:

At 1 year

  • 58% of patients on VYLOY + chemotherapy were still alive
  • 51% of patients on chemotherapy alone were still alive

At 2 years

  • 29% of patients on VYLOY + chemotherapy were still alive
  • 17% of patients on chemotherapy alone were still alive

What are the possible side effects of VYLOY?

Support, tools, and resources are available for anyone receiving VYLOY

What is VYLOY?

IMPORTANT SAFETY INFORMATION

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

  • cannot be removed with surgery or has spread to other parts of the body,
  • is HER2-negative, and
  • your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

  • have nausea or vomiting.
  • are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

  • Allergic reactions, including anaphylaxis and infusion-related reactions. Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions and serious infusion-related reactions that may lead to death. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
  • itchy, raised bumps on the skin (hives)
  • coughing that does not go away
  • nausea or vomiting
  • stomach (abdominal) pain
  • increased saliva
  • breathing problems such as wheezing
  • throat tightness or change in voice
  • fever
  • chest discomfort
  • chills or shaking
  • back pain
  • Severe nausea and vomiting. Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

  • tiredness
  • decreased appetite
  • diarrhea
  • tingling or numbness of the arms or legs
  • stomach (abdominal) pain
  • constipation
  • decreased weight
  • fever
  • decreased white blood cells, red blood cells and platelets
  • decreased protein (albumin) in the blood
  • changes in kidney function tests
  • changes in blood sugar (glucose)
  • changes in liver function tests
  • changes in body salts (electrolytes) in your blood

Your healthcare provider may slow the rate of your infusion, temporarily stop, or completely stop treatment with VYLOY if you have certain side effects. These are not all of the possible side effects of VYLOY. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Patient Information.

What is VYLOY?

IMPORTANT SAFETY INFORMATION

What is VYLOY?

VYLOY is a prescription medicine used to treat adults with cancer of the stomach (gastric cancer) or cancer located where the esophagus joins the stomach (gastroesophageal junction cancer). VYLOY is used in combination with chemotherapy that contains fluoropyrimidine and platinum as the first treatment when your gastric or gastroesophageal junction cancer:

  • cannot be removed with surgery or has spread to other parts of the body,
  • is HER2-negative, and
  • your tumor tests positive for “claudin (CLDN)18.2.”

It is not known if VYLOY is safe and effective in children.

Before receiving VYLOY, tell your healthcare provider about all of your medical conditions, including if you:

  • have nausea or vomiting.
  • are pregnant or plan to become pregnant. It is not known if VYLOY will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if VYLOY passes into your breast milk. Do not breastfeed during treatment with VYLOY and for 8 months after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of VYLOY?

VYLOY may cause serious side effects, including:

  • Allergic reactions, including anaphylaxis and infusion-related reactions. Allergic reactions are common during treatment with VYLOY and can sometimes be serious. Serious allergic reactions can happen during or after your VYLOY infusion, including life-threatening allergic reactions and serious infusion-related reactions that may lead to death. Your healthcare provider will monitor you during your infusion and for 2 hours after or longer if needed. Tell your healthcare provider or get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction during or after your infusion of VYLOY:
  • itchy, raised bumps on the skin (hives)
  • coughing that does not go away
  • nausea or vomiting
  • stomach (abdominal) pain
  • increased saliva
  • breathing problems such as wheezing
  • throat tightness or change in voice
  • fever
  • chest discomfort
  • chills or shaking
  • back pain
  • Severe nausea and vomiting. Nausea and vomiting are common during treatment with VYLOY and can sometimes be severe. Nausea and vomiting happened more often during the first treatment cycle. Before you receive each VYLOY infusion, your healthcare provider will give you medicines to help prevent nausea and vomiting. Tell your healthcare provider right away if nausea or vomiting does not go away or gets worse.

The most common side effects of VYLOY include:

  • tiredness
  • decreased appetite
  • diarrhea
  • tingling or numbness of the arms or legs
  • stomach (abdominal) pain
  • constipation
  • decreased weight
  • fever
  • decreased white blood cells, red blood cells and platelets
  • decreased protein (albumin) in the blood
  • changes in kidney function tests
  • changes in blood sugar (glucose)
  • changes in liver function tests
  • changes in body salts (electrolytes) in your blood

Your healthcare provider may slow the rate of your infusion, temporarily stop, or completely stop treatment with VYLOY if you have certain side effects. These are not all of the possible side effects of VYLOY. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Patient Information.